Abstract
Tumour necrosis factor (TNF) ligands and receptors play a central role in the regulation of immune responses. Aberrant expression or activation of specific TNF ligand or receptor molecules may lead to autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosis. Amgen describes new members of the TNF receptor family, the MK61 series of molecules. Preclinical data demonstrating a role for the MK61 molecules in regulating B cell response to antigens are presented. The clinical utility of either agonists or antagonists of the members of the MK61 family of molecules remains to be proven.